De Chao Yu
Chief Executive Officer presso INNOVENT BIOLOGICS, INC.
Patrimonio netto: 526 M $ in data 31/03/2024
Profilo
Fondatore di Innovent Biologics, Inc. e Chengdu Kanghong Pharmaceutical Group Co., Ltd., De Chao Yu occupa la posizione di presidente e amministratore delegato di Innovent Biologics, Inc. e presidente della Chinese Antibody Society. È anche nel consiglio di amministrazione di Babytree Group e Cheerwin Group Ltd. e professore all'Università di Sichuan. De Chao Yu è stato in precedenza presidente e amministratore delegato di Chengdu Kanghong Pharmaceutical Group Co., Ltd., vicepresidente di ricerca e sviluppo di Applied Genetic Technologies Corp., vicepresidente di ricerca e sviluppo di Applied Genetics, Inc., presidente e amministratore delegato di Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd., Vice Presidente-Ricerca e Sviluppo di Calyon North America, Inc., Vice Presidente di Calydon, Inc. e Direttore Generale di China Medicinal Biotech Association. Ha ricevuto un dottorato dall'Accademia cinese delle scienze.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
INNOVENT BIOLOGICS, INC.
6.73% | 22/03/2024 | 109 245 165 ( 6.73% ) | 526 M $ | 31/03/2024 |
Posizioni attive di De Chao Yu
| Società | Posizione | Inizio |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Chief Executive Officer | 28/04/2011 |
| Sichuan University | Corporate Officer/Principal | 01/01/2008 |
| Chinese Antibody Society | Chairman | 01/01/2017 |
Precedenti posizioni note di De Chao Yu
| Società | Posizione | Fine |
|---|---|---|
| BABYTREE GROUP | Director/Board Member | 10/05/2023 |
| CHEERWIN GROUP LIMITED | Director/Board Member | 14/10/2022 |
| China Medicinal Biotech Association | Corporate Officer/Principal | 01/01/2019 |
| PHARMABLOCK SCIENCES (NANJING), INC. | Director/Board Member | 01/01/2018 |
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Chief Executive Officer | 01/01/2011 |
Formazione di De Chao Yu
| Chinese Academy of Sciences | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Health Technology |
| INNOVENT BIOLOGICS, INC. | Health Technology |
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| BABYTREE GROUP | Commercial Services |
| CHEERWIN GROUP LIMITED | Process Industries |
| Aziende private | 7 |
|---|---|
Calydon, Inc.
 Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The private company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Calyon North America, Inc.
 Calyon North America, Inc. Regional BanksFinance Part of SAS Rue la Boétie, Calyon North America, Inc. is a private company based in New York, NY. | Finance |
| China Medicinal Biotech Association | |
| Applied Genetics, Inc. | |
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd.
 Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ellimist Singapore Pte Ltd., Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. is a pharmaceutical company that manufactures and supplies pharmaceutical products. The private company is based in Chengdu, China. Kanghong Sagent Chengdu Pharmaceutical Corp. was acquired by Sagent Pharmaceuticals, Inc., part of Ellimist Singapore Pte Ltd. from February 28, 2023 on June 04, 2013 for $4.06 million. The Chinese company was founded in 2006. | Health Technology |
| Chinese Antibody Society |
- Borsa valori
- Insiders
- De Chao Yu
